Posted by Michael Wonder on 16 Oct 2022
Mirum Pharmaceuticals announces positive CHMP opinion for Livmarli (maralixibat) oral solution for cholestatic pruritus in patients with Alagille syndrome two months of age and older
14 October 2022 - CHMP opinion based on pivotal ICONIC study with more than five years of data demonstrating durable and clinically meaningful improvements in cholestatic pruritus and serum bile acids for patients with Alagille syndrome.
Mirum Pharmaceuticals today announced two global advancements for Livmarli (maralixibat) oral solution, an oral minimally absorbed ileal bile acid transporter inhibitor currently approved in the US for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.
